Browse articles on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
“Even with the wealth of new technologies available … refractive surprises, longer and shorter eyes, and unique medical histories persist. During these times we are called to flex our expertise and go beyond the routine to meet the needs of these patients,” said Karolinne Rocha, MD, introducing the articles in the Refractive section.
Antibody drug conjugates, an emerging area in cancer therapy, can pose a risk to the eye and cause adverse ocular events. Several experts discussed the research, what they’ve seen in terms of side effects, and considerations for patients taking these drugs and the eyecare providers monitoring them.
The DSLT laser (Voyager, Alcon) became commercially available in the U.S. earlier this year, and many surgeons are beginning to incorporate this into their glaucoma treatment paradigm. Several physicians discussed this new technology, how it compares to SLT, and how they’re using it in their practices.
As the commitment to sustainability in eyecare grows, the importance of educating the next generation of physicians is important. Medical students, residents, and fellows must be trained on best practices for waste reduction in the field. This column outlines the ongoing efforts to educate trainees in ophthalmology.
ASCRS Executive Director Steve Speares pays tribute to ASCRS Immediate Past President Vance Thompson, MD.
Manual marking, digital marking, manual and digital marking—toric IOL alignment methods continue to be an important topic. Both methods still have a place, and both have their pros and cons. Four physicians discussed their preferences.
When it comes to refractive procedures, there are many options available. Several physicians discussed what they’re using and the options available, notably market penetration of the Implantable Collamer Lens (ICL, STAAR Surgical) and SMILE in different areas and how this has changed over the years.
Results from the Zoster Eye Disease Study (ZEDS) were first presented last year. This randomized clinical trial looked at the use of low dose valacyclovir for reducing complications with herpes zoster ophthalmicus. Two cornea specialists spoke to EyeWorld about the results, highlighting recently published papers on findings from the study.
Several physicians discussed the benefits they see with virtual reality visual fields in practice and the potential for artificial intelligence in glaucoma.
Manjool Shah, MD, shared his thoughts on the topics of the Glaucoma articles: the often-asked question about the impact of lifestyle modifications, the increasingly critical imperative of sustainability in practices, and the rapidly advancing world of virtual visual fields and artificial intelligence.